Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • newtoseq
    Junior Member
    • Nov 2014
    • 2

    Questions about whole-exome sequencing on NextSeq 500

    Hi everyone,

    My lab is looking into performing whole-exome sequencing on a small sample of human subjects on the NextSeq 500. I am responsible for researching the budget involved in such an endeavor and, as a newbie to this subject, would like to seek your advice on the number/type of sample prep/reagent kits to achieve our sequencing goals.

    We would like to whole-exome sequence 4-8 (depending on total costs) human subjects at >100x coverage, pair-ended read using the Nextera Rapid Capture Exome Kit and, ideally, the High Output 300 cycle NextSeq Kit.

    So, if we use 1 Nextera Rapid Capture Exome Kit (8rxn x 6plex), which according to documentation at 6plex can sequence 6 exome samples using NextSeq 500 High-Output kit, and 1 NextSeq Kit, High Output (300 cycle), can I whole-exome sequence up to 6 unique human subjects at >100x coverage with pair-ended read?

    edit: As a follow up question, I'm assuming that 1 Nextera Rapid Capture Exome Kit (8rxn x 6plex) can support sequencing of up to 48 exome samples, by the 8 reaction x 6 plex criteria? I apologize for my ignorance, thank you very much for your help.

    Thank you for your help.
    Last edited by newtoseq; 11-02-2014, 08:10 PM.
  • Brian Bushnell
    Super Moderator
    • Jan 2014
    • 2709

    #2
    Are you locked in to the NextSeq platform, or do you have the possibility of using something else?

    Comment

    • newtoseq
      Junior Member
      • Nov 2014
      • 2

      #3
      Originally posted by Brian Bushnell View Post
      Are you locked in to the NextSeq platform, or do you have the possibility of using something else?
      Hi Brian, at this point, we are currently only looking at using the NextSeq 500. Thank you.

      Comment

      • Brian Bushnell
        Super Moderator
        • Jan 2014
        • 2709

        #4
        I encourage you to look at this thread.

        But that aside... I can't help you with the economics. In fact, I think human resequencing is one area where NextSeq might possibly be useful, though it highly depends on the price. Unless NextSeq is vastly cheaper than HiSeq per bp, it's a bad idea, since the error rate is currently so high. Particularly for exome capture, where the coverage is even more highly variable than usual for Illumina, forcing you to call variants at very low coverage.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Today, 11:41 AM
        0 responses
        7 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        21 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        34 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-09-2026, 10:04 AM
        0 responses
        44 views
        0 reactions
        Last Post SEQadmin2  
        Working...